Steven A. Bossone
Corporate Officer/Principal chez ALNYLAM PHARMACEUTICALS, INC.
Profil
Steven A.
Bossone is a professional with experience in the pharmaceutical industry.
He is currently the Vice President-Intellectual Property at Alnylam Pharmaceuticals, Inc. He has previously worked as a Scientist at Millennium Pharmaceuticals, Inc. and Millennium Biotherapeutics, Inc., as a Principal at Tolerx, Inc., and as a Senior Patent Attorney at Shire US, Inc. and EMD Serono, Inc. Bossone holds a doctorate degree from Stony Brook University and a graduate degree from Suffolk University Law School.
Postes actifs de Steven A. Bossone
Sociétés | Poste | Début |
---|---|---|
ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2010 |
Anciens postes connus de Steven A. Bossone
Sociétés | Poste | Fin |
---|---|---|
Millennium Biotherapeutics, Inc. | Directeur Technique/Scientifique/R&D | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Corporate Officer/Principal | - |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Corporate Officer/Principal | - |
Shire US, Inc.
Shire US, Inc. Medical DistributorsDistribution Services Shire US, Inc. sells and markets prescription medicines. The company was founded on September 28, 1983 and is headquartered in Lexington, MA. | Corporate Officer/Principal | - |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | - |
Formation de Steven A. Bossone
Stony Brook University | Doctorate Degree |
Suffolk University Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
Shire US, Inc.
Shire US, Inc. Medical DistributorsDistribution Services Shire US, Inc. sells and markets prescription medicines. The company was founded on September 28, 1983 and is headquartered in Lexington, MA. | Distribution Services |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Millennium Biotherapeutics, Inc. |